Belgium
· Delayed Price · Currency is EUR UCB SA Company Description
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome.
It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis.
Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; UCB0222 for the treatment of Parkinson’s disease; and UCB9741 and UCB1381 for atopic dermatitis.
Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
| Country | Belgium |
| Founded | 1925 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9,378 |
| CEO | Jean-Christophe Tellier |
Contact Details
Address: Allée de la Recherche, 60 Brussels, 1070 Belgium | |
| Phone | 32 2 559 99 99 |
| Website | ucb.com |
Stock Details
| Ticker Symbol | UCB |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0003739530 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jean-Christophe Tellier | Chief Executive Officer and Executive Director |
| Sandrine Dufour CFA | Executive Vice President, Chief Financial Officer and Chief Corporate Development |
| Denelle J. Waynick Johnson J.D. | Executive Vice President and General Counsel |
| Jean-Luc Fleurial | Executive Vice President and Chief Human Resources Officer |
| Emmanuel Caeymaex | Executive Vice President and Chief Commercial Officer |
| Dr. Kirsten Lund-Jurgensen Ph.D. | Executive Vice President of Patient Supply |
| Fiona du Monceau | Executive Vice President of Patient Evidence |
| Caroline Vancoillie | Chief Accounting Officer, Head of Group Finance and Chief Financial Officer of Patient Value Functions |
| Alistair Henry | Executive Vice President and Chief Scientific Officer |
| Antje Witte | Head of Investor Relations |